# A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

> **NCT04667104** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 48 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** JNJ-73763989
- **DRUG:** Tenofovir disoproxil
- **DRUG:** Tenofovir alafenamide (TAF)
- **DRUG:** Entecavir (ETV) monohydrate
- **DRUG:** PegIFN-alpha2a

## Key facts

- **NCT ID:** NCT04667104
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-01
- **Primary completion:** 2022-05-16
- **Final completion:** 2023-04-17
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04667104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04667104, "A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04667104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*